B Kaufman Selected Research

Bevacizumab (Avastin)

11/2014	Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses.
11/2012	Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer.
3/2011	First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

B Kaufman Research Topics

Disease

17	Breast Neoplasms (Breast Cancer) 01/2022 - 03/2001
10	Neoplasms (Cancer) 12/2021 - 01/2000
3	Neoplasm Metastasis (Metastasis) 01/2021 - 11/2008
2	Hemorrhage 01/2021 - 03/2011
2	Ovarian Neoplasms (Ovarian Cancer) 01/2016 - 01/2000
2	Disease Progression 11/2012 - 03/2011
1	Anemia 01/2022
1	Neutropenia 01/2022
1	Encephalitis (Encephalitis, Rasmussen) 12/2021
1	Melanoma (Melanoma, Malignant) 12/2021
1	Thrombocytopenia (Thrombopenia) 01/2021
1	Peripheral Nervous System Diseases (PNS Diseases) 01/2021
1	Acidosis 09/2018
1	Critical Illness (Critically Ill) 09/2018
1	Status Epilepticus (Complex Partial Status Epilepticus) 09/2018
1	Triple Negative Breast Neoplasms 11/2014
1	Pancreatic Neoplasms (Pancreatic Cancer) 09/2014
1	Infections 05/2013
1	Adenocarcinoma 11/2012
1	Hypertension (High Blood Pressure) 03/2011
1	Venous Thromboembolism 03/2011
1	Proteinuria 03/2011
1	Inflammatory Breast Neoplasms 05/2010
1	Pain (Aches) 05/2010
1	Vomiting 03/2010
1	Diarrhea 03/2010
1	Nausea 03/2010
1	Atrophy 06/2007
1	Fibrosis (Cirrhosis) 06/2007
1	Wound Infection (Wound Infections) 05/2003
1	Cellulitis 05/2003
1	Pulmonary Infarction 12/2001
1	Pneumothorax 12/2001
1	Pulmonary Edema 12/2001

Drug/Important Bio-Agent (IBA)

5	AnthracyclinesIBA 01/2021 - 03/2010
4	Paclitaxel (Taxol)FDA LinkGeneric 01/2022 - 11/2012
4	taxaneIBA 01/2021 - 03/2010
3	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2022 - 01/2016
3	Hormones (Hormone)IBA 01/2021 - 01/2010
3	Trastuzumab (Herceptin)FDA Link 01/2021 - 03/2010
3	human ERBB2 proteinIBA 01/2021 - 06/2010
3	Epidermal Growth Factor (EGF)IBA 01/2021 - 11/2008
3	Bevacizumab (Avastin)FDA Link 11/2014 - 03/2011
3	Capecitabine (Xeloda)FDA Link 11/2014 - 03/2010
2	Carboplatin (JM8)FDA LinkGeneric 01/2022 - 01/2018
2	veliparibIBA 01/2022 - 01/2018
2	Fulvestrant (Faslodex)FDA Link 01/2021 - 06/2010
2	N,N'-bis(4-azidobenzoyl)cystineIBA 10/2014 - 10/2014
2	Lapatinib (GW572016)FDA Link 05/2010 - 03/2010
1	ErbB Receptors (EGF Receptor)IBA 01/2022
1	Immune Checkpoint InhibitorsIBA 12/2021
1	Ado-Trastuzumab EmtansineIBA 01/2021
1	PlatinumIBA 01/2021
1	AlpelisibIBA 01/2021
1	Ketamine FDA LinkGeneric 09/2018
1	Temozolomide (Temodar)FDA LinkGeneric 01/2018
1	Biomarkers (Surrogate Marker)IBA 01/2016
1	olaparibIBA 01/2016
1	Biological ProductsIBA 09/2014
1	Peptides (Polypeptides)IBA 05/2013
1	Taxoids (Taxanes)IBA 05/2010
1	Pharmaceutical PreparationsIBA 03/2010
1	Proteins (Proteins, Gene)FDA Link 01/2010
1	CCAAT-Enhancer-Binding Protein-betaIBA 11/2008
1	Growth InhibitorsIBA 11/2008
1	Transcription Factors (Transcription Factor)IBA 11/2008
1	Insulin (Novolin)FDA Link 11/2008
1	Fibroblast Growth Factors (Fibroblast Growth Factor)IBA 11/2008
1	Insulin-Like Growth Factor I (IGF-1)IBA 11/2008
1	Anti-Bacterial Agents (Antibiotics)IBA 05/2003
1	5' Untranslated Regions (5' UTR)IBA 03/2001

Therapy/Procedure

6	Therapeutics 01/2022 - 05/2003
3	Drug Therapy (Chemotherapy) 01/2016 - 06/2007
1	Neoadjuvant Therapy 01/2021
1	Mastectomy (Mammectomy) 01/2019
1	Segmental Mastectomy (Lumpectomy) 05/2003
1	Central Venous Catheters 12/2001
1	Catheters 12/2001
1	Palliative Care (Palliative Therapy) 11/2000
1	Chemoprevention 01/2000